Clinical Trials

Prostatic Neoplasms

NCT01619813 2023-08-04

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

85 enrolled

Prostatic Neoplasms

NCT01708993 2023-08-04

Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

166 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00042939 2023-07-06

Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer

94 enrolled 10 charts

Pancreatic Neoplasms

NCT00551759 2023-07-03

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

Phase 2 Terminated

22 enrolled 5 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT01824901 2023-06-29

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

Phase 1/2 Completed

2 enrolled 4 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00004223 2023-06-18

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00003519 2023-06-15

Combination Chemotherapy in Treating Women With Breast Cancer

2,778 enrolled

Breast Neoplasms

NCT00003810 2023-06-15

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

Pancreatic Neoplasms

NCT00004125 2023-06-15

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Breast Neoplasms

NCT00027859 2023-06-15

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Prostatic Neoplasms

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02607423 2023-05-25

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02766335 2023-05-25

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Phase 2/3 Completed

116 enrolled 23 charts

Recurrent Squamous Cell Lung Carcinoma

NCT01726452 2022-09-30

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

377 enrolled

Esophageal Neoplasms

NCT00288080 2022-06-21

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

612 enrolled 11 charts

Prostatic Neoplasms

NCT00887536 2022-04-20

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

1,613 enrolled

Adenocarcinoma, Breast Diseases, Breast Neoplasms, Carcinoma

NCT01547741 2022-04-14

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Phase 3 Unknown

1,871 enrolled

Breast Neoplasms

NCT00134056 2021-10-27

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

1,038 enrolled 20 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

105 enrolled 17 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02965378 2021-05-27

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2/3 Completed

43 enrolled 15 charts

FGFR1 Gene Amplification

NCT01160705 2020-11-17

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

Completed

73 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT00030654 2020-10-22

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

21 enrolled

Prostatic Neoplasms

NCT00625898 2020-09-10

BETH

Phase 3 Terminated

3,509 enrolled

Breast Neoplasms

NCT00002866 2020-04-01

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

Phase 1 Completed

50 enrolled

Breast Neoplasms, Neutropenia

NCT01099436 2020-01-21

NEO-ZOTAC

250 enrolled

Breast Neoplasms

NCT01498289 2019-11-07

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

213 enrolled 17 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT00911716 2019-08-01

TC Avastin. ICORG 08-10, V6

Phase NA Completed

106 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT02718482 2019-05-13

OsteoREC2015

Phase 2 Terminated

7 enrolled

Sarcoma

Osteosarcoma

NCT00528866 2019-04-24

Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

80 enrolled 11 charts